Russ Mould, investment director at AJ Bell, said: “Things may not have got any worse since November’s disappointing update but it’s no shock to see Hikma Pharmaceuticals CEO Riad Mishlawi head for the exit.
“The shares have lost more than a quarter of their value in 2025.
“The most damaging part of last month’s trading statement was the reduction in medium-term profit growth expectations – which forced a broader reassessment of the investment case than a mere blip in trading would have done.
“The company faces tough competition in the generic drugs space, but it also has been the master of its own downfall thanks to delays to a new UK manufacturing facility and issues in its supply chain.
“In this context it is not a surprise to see Mishlawi, who has served with the company for decades and the last two years as CEO, carry the can and move into retirement.
“Investors will hope the return of former boss Said Darwazah, who had been serving as executive chair, can inject renewed purpose into the business.”
Contact details are available to account holders.
Create a free account to get in touch with this expert.